Insomnia News and Research

Latest Insomnia News and Research

Integrative Medicine helps people heal faster

The body has an innate desire to heal itself. Encouraging self-healing is the focus of Greenwich Hospital's Integrative Medicine Program.

19 Oct 2012

Antipsychotic drug exposure may have neurologic consequences

French researchers report an increased risk for Parkinson’s disease in elderly people who have past exposure to neuroleptic drugs.

16 Oct 2012

MDD with subthreshold hypomania ‘should be merged with bipolar II’

Patients with major depressive disorder plus subthreshold hypomania exhibit significant differences in disease course, symptoms, treatment-seeking rates, and other characteristics compared with those with major depression alone, research shows.

11 Oct 2012

MDD with subthreshold hypomania ‘should be merged with bipolar II’

Patients with major depressive disorder plus subthreshold hypomania exhibit significant differences in disease course, symptoms, treatment-seeking rates and other characteristics compared with those with major depression alone, research shows.

10 Oct 2012

Benzodiazepine exposure for over-65s linked to increased risk of dementia

The results from comparative analysis of this population demonstrate the risk of developing dementia increased by 50% for subjects who consumed benzodiazepines during the follow-up period, compared with those who had never used benzodiazepines.

6 Oct 2012

Gateway Foundation to raise awareness of synthetic drug use

In recognition of Red Ribbon Week, October 23-31, 2012, Gateway Foundation Alcohol & Drug Treatment is working to build awareness among communities regarding the dangerous health risks associated with synthetic drug use.

4 Oct 2012

New studies reveal real economic and human costs of caring for cancer patients in Europe

New studies that reveal for the first time the real economic and human costs of caring for cancer patients in Europe will be presented during the ESMO 2012 Congress of the European Society for Medical Oncology in Vienna.

29 Sep 2012

Seattle conference to focus on trauma and addiction treatment

The incidence of trauma and abuse has truly reached epidemic proportions, and those who suffer trauma sometimes turn to alcohol or other drugs to manage post-traumatic stress symptoms like nightmares, anxiety, insomnia, and dissociation.

29 Sep 2012

Melatonin supplementation improves sleep in hypertensive patients on beta-blockers

Over 20 million people in the United States take beta-blockers, a medication commonly prescribed for cardiovascular issues, anxiety, hypertension and more. Many of these same people also have trouble sleeping, a side effect possibly related to the fact that these medications suppress night-time melatonin production. Researchers at Brigham and Women's Hospital (BWH) have found that melatonin supplementation significantly improved sleep in hypertensive patients taking beta-blockers.

28 Sep 2012

Anxiety, depression and insomnia drugs and risk of driving accident: an interview with Hui-Ju Tsai

Anxiety, depression and insomnia drugs have been commonly used to treat mental and emotional disorders, or improve sleep-related problems.

27 Sep 2012

Combination of two neuroprotective therapies shows promise against Alzheimer's

The combination of two neuroprotective therapies, voluntary physical exercise, and the daily intake of melatonin has been shown to have a synergistic effect against brain deterioration in rodents with three different mutations of Alzheimer's disease.

27 Sep 2012

InterCure signs strategic service agreement with private company

XTL Biopharmaceuticals Ltd. today announced that InterCure Ltd., which is approximately 45.4% (50.79% on a fully diluted basis) held by XTL, signed a strategic service agreement with a private company wholly owned by Mr. Shay Ben Yitzhak and Mr. Avner Yassur.

25 Sep 2012

Combination of healing touch and guided imagery reduces depression, cynicism among US Marines

Healing touch combined with guided imagery (HT+GI) provides significant clinical reductions in post-traumatic stress disorder (PTSD) symptoms for combat-exposed active duty military, according to a study released in the September issue of Military Medicine.

25 Sep 2012

Sleep medicine and research: an interview with James K. Walsh

There are a variety of sleep medicines. I am going to refer to what are commonly described as hypnotics or sleeping pills. Sleeping pills have been around for a long time.

24 Sep 2012

Drugs to treat anxiety, depression and insomnia may increase risk of driving accident

Drugs prescribed to treat anxiety, depression and insomnia may increase patients’ risk of being involved in motor vehicle accidents, according to a recent study, published in the British Journal of Clinical Pharmacology. Based on the findings, the researchers suggested doctors should consider advising patients not to drive while taking these drugs.

13 Sep 2012

GPs not always using reliable online resources for information on tinnitus

GPs are not always using the most comprehensive and reliable online resources to support them in treating patients with the debilitating hearing condition tinnitus, researchers have found.

13 Sep 2012

Exposure to road traffic noise may increase risk of annoyance or sleep disturbance

The World Health Organization recently recognized environmental noise as harmful pollution, with adverse psychosocial and physiological effects on public health. A new study of noise pollution in Fulton County, Georgia, suggests that many residents are exposed to high noise levels that put them at risk of annoyance or sleep disturbance, which can have serious health consequences.

12 Sep 2012

Four steps to help curb military suicide

The suicide rate in the U.S. Army now exceeds the rate in the general population, and psychiatric admission is now the most common reason for hospitalization in the Army.

11 Sep 2012

Phase III data for Suvorexant, an investigational insomnia medicine, announced

Merck (NYSE: MRK), known as MSD outside the United States and Canada, today announced new data for suvorexant, the investigational medicine Merck is developing for the treatment of insomnia. The new data are from one of the longest, continuously-dosed, placebo-controlled trials of a sleep medication ever conducted.

10 Sep 2012

Heptares uses StaR technology to solve structure of CRF-1 receptor

Heptares Therapeutics today announces that it has used its StaR technology to solve entirely in-house the first structure of a Family B sub-class G protein-coupled receptor (GPCR).

10 Sep 2012